The short version of GHRH analogue fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-28. Anything still debated is marked as such rather than presented as settled.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
==== MeSH D13.570.685 – pyrimidine nucleosides ==== MeSH D13.570.685.245 – cytidine MeSH D13.570.685.245.217 – azacitidine MeSH D13.570.685.245.453 – cytarabine MeSH D13.570.685.245.453.050 – ancitabine MeSH D13.570.685.245.500 – deoxycytidine MeSH D13.570.685.245.500.250 – bromodeoxycytidine MeSH D13.570.685.245.500.950 – zalcitabine MeSH D13.570.685.245.500.950.500 – lamivudine MeSH D13.570.685.350 – formycins MeSH D13.570.685.350.200 – coformycin MeSH D13.570.685.350.200.700 – pentostatin MeSH D13.570.685.705 – thymidine MeSH D13.570.685.705.875 – stavudine MeSH D13.570.685.705.900 – trifluridine MeSH D13.570.685.705.950 – zidovudine MeSH D13.570.685.725 – tunicamycin MeSH D13.570.685.852 – uridine MeSH D13.570.685.852.150 – arabinofuranosyluracil MeSH D13.570.685.852.176 – azauridine MeSH D13.570.685.852.250 – 3-deazauridine MeSH D13.570.685.852.300 – deoxyuridine MeSH D13.570.685.852.300.150 – bromodeoxyuridine MeSH D13.570.685.852.300.350 – floxuridine MeSH D13.570.685.852.300.400 – idoxuridine MeSH D13.570.685.852.628 – pseudouridine MeSH D13.570.685.852.800 – tetrahydrouridine MeSH D13.570.685.852.829 – thiouridine
== Environmental factors == Living in an environment with more green spaces is associated with higher well-being, partly due to the beneficial effects on psychological relaxation, stress alleviation, increased physical activity, and reduced exposure to air pollutants and noise, among others. According to the latest systematic review of the economic literature on life satisfaction, pollution is bad for one's well-being. Exposure to outdoor air pollution and chimney smoke fireplaces causes dementia and other-health risks. Climate change mitigation measures have mostly positive direct effects on human well-being.
== Animal feed == FDA permits a certain amount of cyanuric acid to be present in some non-protein nitrogen (NPN) additives used in animal feed and drinking water. Cyanuric acid has been used as NPN. For example, Archer Daniels Midland manufactures an NPN supplement for cattle, which contains biuret, triuret, cyanuric acid and urea.
== Episode 5: A Question of Trust == Lashay Hamblin is a 16-year-old high school student at the time of filming the episode. She suffers from an illness with similarities to Bulimia, only she has no control over her actions. Everything that Lashay eats or drinks is almost immediately thrown up and she had very bad stomach cramping because of it. She expresses her bad experience with physicians who did not want to diagnose her because at only 16 years old she shows an almost exact reflection of an eating disorder. During her adolescence in 2014 her family went on a trip to Costa Rica where she had an encounter with a wild raccoon that tore at her skin. When she got back home from the trip only two days later she had severe symptoms of vomiting, headaches, neck pains and stomach pains. At first physicians thought it was rabies and immediately gave her the rabies vaccination, this however made everything extremely worse and all her symptoms progressed. Since that day in the emergency room she has yet to recover or improve from any of the symptoms. She's not able to walk straight up, sit in a chair, and has a constant throbbing headache. Due to her conditions doctors decided to implant a chest port to be able to provide her with the nutrients and hydration she needs to survive. One physician the family met with suggested she might have a Cerebral Spinal Fluid Leak that would only explain her constant headaches and dizziness.
The new 37th district is based in all but the westernmost parts of Austin, with virtually all of the precincts of the exclusively Travis County-based district favoring Democrats to varying degrees; the new district has a White plurality with a 34% Hispanic voting age population. The incumbent is Democrat Lloyd Doggett, who was re-elected with 75.9% of the vote in 2024. On August 21, 2025, Doggett announced that he would not seek re-election due to mid-decade redistricting, and fellow Democratic Rep. Greg Casar being moved into the 37th district. On August 25, 2025, Casar announced his bid for re-election from this district. Kamala Harris won 76.8% of the vote in the new 37th District, which also gave 79.2% of the vote to Colin Allred; in both cases, the highest of any district amongst the state's new congressional districts.
Sources: en.wikipedia.org
Type I : Extra-dural; no nerve roots or rootlets such as intra-sacral meningoceles; probably of congenital origin developing from the dural sac to which they are connected by a little collar. They are found at the point of exit of a dorsal nerve root from the dural sac. They are sometimes difficult to identify and can be "seen" as a type II cyst on imaging. These cysts are often associated with foramina enlargement and scalloping of the vertebrae. It is very important to distinguish them from sacral meningoceles going to the pelvic area; they are often associated with other congenital abnormalities (teratomes, dermoïdes, lipomas, and other abnormalities(uro-genital and ano-rectal)) Type II: Extra-dural; nerve root present (such as Tarlov or perineural cysts). There are often not only one but multiple cysts, mostly found in the sacrum area. There are two types: Tarlov (perineural) cysts are located posteriorly to the root ganglion, with nerve fibres inside or nerve tissue in the walls; they are not communicating with the perineural arachnoid space. Type-II cysts are very small in the upper sacral area, but can be bigger (up to 3 centimetres or 1.2 inches) if found located in the lower part of the sacrum. The second variant of type-II cysts are called "meningeal diverticula". They are located anteriorly to the nerve root ganglion, with nerves fibres inside and communicating with the subarachnoid space. Type III: intra-dural; these are either congenital or caused by trauma; they are rarely associated with other abnormalities and rare in occurrence.
=== Phase 1/2 === XC-101 (XC101; XC101-D13H) – serotonin 5-HT1B and 5-HT7 receptor agonist, serotonin 5-HT1D and 5-HT1F receptor partial agonist, and serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor antagonist – migraine [29]
=== Interwar years (1919-1941) === Following the Ottoman Empire's post-World War I dismemberment and the foundation of the successor Turkish Republic in 1923, Mustafa Kemal Atatürk banned all Sufi orders and installed the Directorate of Religious Affairs as sole governing entity over religion. Bektashi lodges in Turkey were subsequently closed in 1925, with the order's leadership relocating to Albania and establishing its headquarters in Tirana. Salih Nijazi was the last Dedebaba in Turkey and the first in Albania, formerly appointed to his role in the latter country on 30 March 1930. The order became involved in Albanian politics, and some of its members, including Ismail Qemali, were major leaders of the Albanian National Awakening (Rilindja). After the lodges in Turkey were shut down, the order's headquarters moved to Albania. On 20 March 1930, Salih Nijazi was elected as the Dedebaba of the Bektashi community in Albania. Before Nijazi, the Dedebaba was Haxhi Fejzullah in Turkey. Njazi established the Bektashi World Headquarters in Tirana. Its construction was finished in 1941 during the Italian occupation of Albania. Nijazi promoted Bektashi Islam by introducing major ceremonies at popular tekkes. After he was murdered in 1941, Ali Riza succeeded him as the Dedebaba.
March: Decree on feudal successions, abolishing primogeniture and affirming gender equality in inheritance. May–June: Decree establishing relief workshops for beggars, differentiated by sex, age, and health (women and children assigned to spinning rather than agricultural workshops). August: Requirement for public prosecutor's hearing if a married woman (or ward, minor, or legally incapacitated person, male or female) is involved in judicial proceedings.
Forequarter Neck – neck chops Shoulder – shoulder chops, shoulder roast (usually boned and rolled) Rib-eye Breast Knuckle Loin Rib-loin – racks, frenched cutlets, spare ribs Mid-loin – striploin (backstrap), loin chops Tenderloin Flap Full leg – leg roast (may be boned and rolled), leg chops. A short-cut leg is a full leg without the chump; a carvery leg is a short-cut leg without the thick flank Chump (rump) – chump chops, rump steak Thick flank (knuckle) – schnitzel Topside & silverside – steaks Shank
Sources: en.wikipedia.org
is the area of the surface on contact. Pressure is a scalar quantity. It relates the vector area element (a vector normal to the surface) with the normal force acting on it. The pressure is the scalar proportionality constant that relates these two normal vectors:
Vayda (1952), professor emeritus of anthropology and ecology at Rutgers University Melvin Ember (1953), professor of the City University of New York and editor of Cross-Cultural Research Julian Wolpert (1953), professor of urban planning at the Princeton School of Public and International Affairs Demetrios James Caraley (1954), editor of Political Science Quarterly and president of the Academy of Political Science Peter Kenen (1954), provost, Columbia University and expert in Optimum currency area theory Henry Littlefield (1954), educator, author, historian who initiated political interpretations of The Wonderful Wizard of Oz Stephen Orgel (1954), Shakespeare and Renaissance literature scholar David Rosand (1954), art historian, Columbia University Haldon Chase (1955), Denver-based archeologist, early figure of the Beat Generation Warren I. Cohen (1955), historian at University of Maryland, Baltimore County Harry N. Scheiber (1955), professor and director of the Institute for Legal Research at the UC Berkeley School of Law Jerry Fodor (1956), philosopher at Rutgers University Roy Lubove (1956), professor of social welfare at the University of Pittsburgh Seymour J.
== Further reading == Bachner, Paul (2021). In further pursuit of excellence: the college of American pathologists 1946-2020 (PDF) (1st ed.). Northfield: College of American Pathologists. ISBN 978-1-941096-61-1.
An enkephalin is a pentapeptide involved in regulating nociception (pain sensation) in the body. The enkephalins are termed endogenous ligands, as they are internally derived (and therefore endogenous) and bind as ligands to the body's opioid receptors. Discovered in 1975, two forms of enkephalin have been found, one containing leucine ("leu"), and the other containing methionine ("met"). Both are products of the proenkephalin gene:
=== Parkinson's disease === In its oral and ODT forms, selegiline is used to treat symptoms of Parkinson's disease (PD). It is most often used as an adjunct to medications such as levodopa (L-DOPA), although it has been used off-label as a monotherapy. The rationale for adding selegiline to levodopa is to decrease the required dose of levodopa and thus reduce the motor complications of levodopa therapy. Selegiline delays the point when levodopa treatment becomes necessary from about 11 months to about 18 months after diagnosis. There is some evidence that selegiline acts as a neuroprotective and reduces the rate of disease progression, though this is disputed. In addition to parkinsonism, selegiline can improve symptoms of depression in people with Parkinson's disease. There is evidence that selegiline may be more effective than rasagiline in the treatment of Parkinson's disease. This may be due to pharmacological differences between the drugs, such as the catecholaminergic activity enhancer (CAE) actions of selegiline which rasagiline lacks.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.